Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theraclone Sciences has dosed first patient in a randomized, double-blind, dose-escalation Phase 1 trial investigating TCN-032 as a treatment for influenza A virus.
Subscribe to our email newsletter
TCN-032 was discovered utilizing Theraclone’s I-STAR platform.
The trial aims to investigate the safety profile of a single intravenous administration of TCN-032 compared to placebo.
The study expects to recruit aorund 40 volunteers at a single US site and will also provide pharmacokinetic and immunogenicity data.
Theraclone executive chairman and acting CEO Steven Gillis said I-STAR has repeatedly demonstrated an ability to identify natural human antibodies with exceptionally biologic activity and therapeutic potential.